![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1523-1755&client=dukeuniv)
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Publication
, Journal Article
Rondeau, E; Scully, M; Ariceta, G; Barbour, T; Cataland, S; Heyne, N; Miyakawa, Y; Ortiz, S; Swenson, E; Vallee, M; Yoon, S-S; Kavanagh, D ...
Published in: Kidney Int
May 2021
Duke Scholars
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
May 2021
Volume
99
Issue
5
Start / End Page
1244
Location
United States
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rondeau, E., Scully, M., Ariceta, G., Barbour, T., Cataland, S., Heyne, N., … 311 Study Group, . (2021). Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296. Kidney Int, 99(5), 1244. https://doi.org/10.1016/j.kint.2021.03.008
Rondeau, Eric, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, et al. “Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.” Kidney Int 99, no. 5 (May 2021): 1244. https://doi.org/10.1016/j.kint.2021.03.008.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296. Kidney Int. 2021 May;99(5):1244.
Rondeau, Eric, et al. “Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.” Kidney Int, vol. 99, no. 5, May 2021, p. 1244. Pubmed, doi:10.1016/j.kint.2021.03.008.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H, 311 Study Group. Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296. Kidney Int. 2021 May;99(5):1244.
![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1523-1755&client=dukeuniv)
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
May 2021
Volume
99
Issue
5
Start / End Page
1244
Location
United States
Related Subject Headings
- Urology & Nephrology
- 3202 Clinical sciences
- 1103 Clinical Sciences